Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05377840 · ClinicalTrials.gov registry record · NA

Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)

A NA study of Crohn Disease and Ulcerative Colitis (UC), sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
152
Enrollment target
1
Study location

NCT05377840 is a NA study of Crohn Disease and Ulcerative Colitis (UC) that is actively recruiting participants, run by Yale University. The registered enrollment target is 152 participants, below the 203-participant average among 71 other Crohn Disease trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05377840, a NA study of Crohn Disease and Ulcerative Colitis (UC), is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
152 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, single center, randomized treatment study to assess if anxiety and depression in participants with IBD can be improved with CBT compared to those treated with SKY.

Interventions

  • BEHAVIORAL Psychologist-administered Cognitive Behavioral Therapy
  • BEHAVIORAL Self-Administered Cognitive Behavioral Therapy

Study Locations (1)

Connecticut

  • Yale New Haven Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2022-07-05
Est. Completion 2025-12
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT05377840

The ClinicalTrials.gov registry entry for NCT05377840 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 71 other Crohn Disease trials with a reported enrollment target (25% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Psychologist-administered Cognitive Behavioral Therapy is the first listed.

NCT05377840 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05377840 about?

NCT05377840 is a clinical study titled "Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)". This is a prospective, single center, randomized treatment study to assess if anxiety and depression in participants with IBD can be improved with CBT compared to those treated with SKY.

What is the current status of trial NCT05377840?

This trial is currently recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2022-07-05. Estimated completion is 2025-12.

What conditions does trial NCT05377840 study?

This clinical trial studies the following conditions: Crohn Disease, Ulcerative Colitis (UC).

What interventions are being tested in trial NCT05377840?

The interventions under investigation include: Psychologist-administered Cognitive Behavioral Therapy (BEHAVIORAL), Self-Administered Cognitive Behavioral Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT05377840?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05377840 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.